Abeona registers long-term safety registry for ZEVASKYN gene therapy in RDEB

Abeona Therapeutics posted one new registry study during the week covering its approved RDEB gene therapy.

• Abeona registered a post-marketing observational registry (NCT07700966) for patients treated with prademagene zamikeracel, also known as ZEVASKYN or pz-cel, for recessive dystrophic epidermolysis bullosa. The study is designed to evaluate long-term safety and wound healing durability for up to 15 years in treated participants¹, with an estimated enrollment of 250 participants across 4 U.S. sites, and status listed as recruiting.